Real-world efficacy and safety profile of four JAK inhibitors in rheumatoid arthritis: a French single-center observational study

Study limitation reported by the research below: “Adverse events not leading to discontinuation were not systematically captured, so non-severe infections and minor adverse effects are likely underreported.”